Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.

7 , 27 , 31 Median progression‐free survival was 16 months for Rd and 38 months for VRd in high‐risk patients, but due to the small sample size (N = 44), the difference did not reach statistical significance. 32 IMID‐based and PI/IMID regimens have also shown favorable outcomes in high‐risk NDMM patients, although supporting data are limited compared to those in patients with relapsed or refractory disease. 7 , 33 , 34 , 35 The use of maintenance therapy in our study was low, without significant differences between cohorts over time.

also in 111,027 other papers